Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhilong Huoxue Tongyu Capsule is a traditional Chinese medicine (TCM) oral capsule formulation used primarily for promoting blood circulation, removing blood stasis, and unblocking meridians. It is indicated for the recovery period of ischemic stroke (arteriosclerotic cerebral infarction) in patients diagnosed with Qi deficiency and blood stasis syndrome according to TCM principles. Clinical symptoms include hemiplegia, numbness on one side of the body, facial paralysis, and speech difficulties[1][7]. The formula contains multiple herbal ingredients such as Astragalus membranaceus (Huangqi), Whitmania pigra (Shuizhi/leech), Ligusticum chuanxiong (Chuanxiong), Angelica sinensis (Danggui), Carthamus tinctorius (Honghua/safflower), Prunus persica seed (Taoren/peach kernel), Paeonia veitchii root (Chishao/red peony root), Aucklandia lappa root (Muxiang/costus root), Acorus tatarinowii rhizome (Shichangpu/sweet flag rhizome), Pheretima aspergillum earthworm extract (Dilong/earthworm extract), Taxillus chinensis stem with leafs parasitic on mulberry tree branchlets or leaves(Sangjisheng/mulberry mistletoe) and Acanthopanax senticosus extractum(Eleutherococcus senticosus)[7]. Pharmacological studies suggest that the capsule exerts neuroprotective effects in animal models of intracerebral hemorrhage by reducing brain injury and inflammation. Mechanistically, it downregulates pro-inflammatory cytokines such as interleukin-1β and tumor necrosis factor-alpha at both protein and mRNA levels[6][3], modulates long non-coding RNAs involved in neural injury response[3][6], inhibits nuclear factor kappa B signaling pathway activation[4], suppresses NLRP3 inflammasome expression[4], regulates oxidative stress responses, promotes angiogenesis via vascular endothelial growth factor A pathways, influences apoptosis-related genes/proteins such as MMP9/NOS3/L6/TNF/CCL2/VEGFA through multi-target actions involving AGE-RAGE/HIF-1/Apelin signaling pathways[5]. The product is widely used clinically in China for treating ischemic stroke recovery phase with evidence also supporting its use in atherosclerosis management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhilong huoxue tongyu capsule.